ERBB2 and gastric cancer: In gastric cancer cell lines, response to lapatinib correlated significantly with HER2 expression: in only HER2-amplified SNU-216 and NCI-N87, 2 out of 11 cell lines were sensitive to lapatinib, and it caused G1-phase shift (~50–80%) and an increase in the expression levels of cell cycle inhibitor p27KIP1, as well as the downregulation of cMyc and Cyclin D [106].